Wall Street brokerages predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will report $59.70 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with estimates ranging from $56.90 million to $64.00 million. Vanda Pharmaceuticals reported sales of $53.04 million during the same quarter last year, which would suggest a positive year over year growth rate of 12.6%. The firm is expected to report its next quarterly earnings results on Wednesday, February 12th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year sales of $225.87 million for the current fiscal year, with estimates ranging from $223.10 million to $230.00 million. For the next year, analysts expect that the company will post sales of $275.13 million, with estimates ranging from $248.30 million to $327.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the Zacks’ consensus estimate of $0.07 by $1.77. Vanda Pharmaceuticals had a net margin of 55.49% and a return on equity of 38.90%. The company had revenue of $59.49 million for the quarter, compared to analysts’ expectations of $58.33 million. During the same quarter in the prior year, the company posted $0.13 earnings per share. Vanda Pharmaceuticals’s revenue for the quarter was up 21.1% compared to the same quarter last year.
NASDAQ VNDA traded up $0.01 during trading hours on Friday, reaching $16.41. The company had a trading volume of 291,283 shares, compared to its average volume of 540,622. The stock has a 50-day moving average of $16.55 and a 200 day moving average of $14.55. Vanda Pharmaceuticals has a 1-year low of $11.83 and a 1-year high of $31.30. The stock has a market capitalization of $875.31 million, a P/E ratio of 34.19 and a beta of 0.35.
Several institutional investors and hedge funds have recently modified their holdings of VNDA. North Star Investment Management Corp. acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth about $66,000. Meeder Asset Management Inc. lifted its position in shares of Vanda Pharmaceuticals by 1,638.3% during the third quarter. Meeder Asset Management Inc. now owns 5,215 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 4,915 shares in the last quarter. Clarus Wealth Advisors acquired a new stake in Vanda Pharmaceuticals in the third quarter valued at approximately $133,000. Pacer Advisors Inc. acquired a new stake in Vanda Pharmaceuticals in the second quarter valued at approximately $138,000. Finally, Zebra Capital Management LLC acquired a new stake in Vanda Pharmaceuticals in the second quarter valued at approximately $170,000. 99.29% of the stock is currently owned by institutional investors and hedge funds.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Recommended Story: How can investors invest in the S&P/TSX Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.